Global Benign Prostatic Hyperplasia Surgical Treatment Market Outlook
Revenue, 2024
$12.5B
Forecast, 2034
$21.5B
CAGR, 2025 - 2034
5.6%
The Benign Prostatic Hyperplasia Surgical Treatment industry revenue is expected to be around $13.2 billion in 2025 and expected to showcase growth with 5.6% CAGR between 2025 and 2034. Modern BPH management depends on surgical treatment of benign prostatic hyperplasia because the male population ages and people become more aware of lower urinary tract symptoms while urology devices improve safety and treatment results. The rising number of prostate enlargement diagnoses along with physician reliance on evidence based BPH treatment protocols drives steady market demand for both medical and surgical options which include alpha blockers that reached $6.58 billion in sales during 2024.
The surgical treatment of benign prostatic hyperplasia includes multiple BPH surgery interventions which help patients with moderate to severe disease achieve durable symptom relief and better urinary flow and enhanced life quality. The main procedural options for BPH treatment include traditional transurethral resection of the prostate and modern minimally invasive procedures and advanced laser prostate surgery systems which deliver precise tissue extraction with minimal bleeding and fast recovery times. The medical field now uses these procedures to treat patients in various healthcare settings which range from hospital inpatient units to day care facilities that provide efficient outpatient care and home based follow up services. The healthcare industry faces two main factors which drive treatment demand healthcare providers now use advanced energy based systems and patients choose minimally invasive procedures because of their safety and fast recovery times and healthcare providers use optimized medical therapy pathways for BPH treatment. The medical field experiences increasing demand because patients want treatments that provide effective results with minimal risks and short recovery periods.
Market Key Insights
The Benign Prostatic Hyperplasia Surgical Treatment market will expand from $12.5 billion in 2024 to $21.5 billion during the period from 2024 to 2034. The market will expand at a 5.6% annual rate because more people will need treatment in Hospital Settings and Ambulatory Clinics and Home Care facilities.
Boston Scientific, Teleflex Incorporated, and PROCEPT BioRobotics are among the leading players in this market, shaping its competitive landscape.
The Benign Prostatic Hyperplasia Surgical Treatment market leads with the United States and China as its main markets which will experience growth at rates between 3.6% and 5.4% from 2024 to 2030.
The market research predicts Brazil, India and South Korea will experience the highest growth rates at 6.4% to 7.7% CAGR.
Transition like Shift to Minimally Invasive Care has greater influence in U.S. and China market's value chain; and is expected to add $545 million of additional value to Benign Prostatic Hyperplasia Surgical Treatment industry revenue by 2030.
.The Benign Prostatic Hyperplasia Surgical Treatment market will experience $9.0 billion growth during 2024-2034 because manufacturers focus on Ambulatory surgery centers & clinics & Home care settings Application for market expansion.
With
rising geriatric male population and expanding awareness of urinary symptom management accelerating adoption of benign prostatic hyperplasia surgical treatment worldwide, and
Technological innovations in minimally invasive benign prostatic hyperplasia surgical treatment improving safety, efficacy, and patient recovery outcomes, Benign Prostatic Hyperplasia Surgical Treatment market to expand 72% between 2024 and 2034.
Opportunities in the Benign Prostatic Hyperplasia Surgical Treatment
The worldwide market for alpha blockers reached 6.58 billion in 2024 before it expanded to 8.87 billion by 2030 while 5 alpha reductase inhibitors will grow from 3.90 to 5.41 billion and other drugs will increase from 1.99 to 3.02 billion yet numerous patients continue to experience symptoms. European urologists now support surgical intervention for benign prostatic hyperplasia at earlier stages because medications have also reached their maximum effectiveness. The Western European market shows the highest interest in two prostate surgery options which receive guidelines approval transurethral resection of the prostate and long lasting minimally invasive prostate surgery systems.
Growth Opportunities in North America and Asia-Pacific
In North America, an aging male population, high diagnostic rates, and strong reimbursement for invasive BPH procedures drive the demand for Benign Prostatic Hyperplasia Surgical Treatment. The demand for prostatic hyperplasia surgical treatment makes ambulatory surgery centers and clinics the most influential end user segment because care moves from inpatient to outpatient settings. Top opportunities include positioning BPH surgery platforms for same day discharge, integrating laser prostate surgery systems with data driven outcome tracking, and expanding service bundles that support procedure standardization across urology group practices. Competition is intense, with advanced technologies well established, so success will depend on demonstrating superior cost effectiveness, reducing retreatment rates, and enabling streamlined workflows that allow ambulatory surgery centers to increase daily case volumes. Additional growth can be captured by partnering with telehealth providers and home care settings to support pre and post operative pathways for prostatic urethral lift and other office based interventions, strengthening brand loyalty along the full continuum of Benign Prostatic Hyperplasia Surgical Treatment.
The Asia Pacific region shows fast growing healthcare facilities and increasing patient understanding of urinary issues which makes large urban hospitals the main End user for benign prostatic hyperplasia surgical procedures while ambulatory surgery centers and clinics become important in Japan and South Korea and Australia. The market requires vendors to develop affordable BPH surgery systems which public and private hospitals can scale up for their high patient volumes through modular laser prostate surgery platforms and minimally invasive BPH procedures that shorten hospital stays and increase available bed capacity. The North American market shows less competition because multinational device manufacturers face competition from agile regional companies which enables vendors to establish themselves through customized training programs and financial solutions and educational services for urologists. The growing middle class and increasing health insurance coverage will create opportunities for vendors to develop organized home care facilities which will enable them to provide complete post surgical care packages including implants and consumables and remote monitoring solutions for long term lower urinary tract symptom management.
Market Dynamics and Supply Chain
01
Driver: Rising geriatric male population and expanding awareness of urinary symptom management accelerating adoption of Benign Prostatic Hyperplasia Surgical Treatment worldwide
The increasing number of elderly men in the population also creates an essential need for BPH surgical procedures because prostate enlargement during aging leads to severe lower urinary tract symptoms that pharmacological treatment fails to control thus driving more patients to seek BPH surgery and supporting the growth of transurethral resection of the prostate and laser prostatectomy procedures and other evidence based treatments. Patients and their primary care providers now understand urinary symptom management better which leads them to choose minimally invasive BPH procedures for early intervention because these treatments provide lasting symptom improvement with minimal side effects. The BPH surgical treatment market will also experience sustained expansion because educational programs and standardized diagnostic methods and improved access to specialized urology equipment enhance procedural success rates and decrease treatment duration and expand treatment access for more patients.
The healthcare system faces reduced expenses because device based and energy based platforms continue to advance at a fast pace which enables surgeons to perform less invasive procedures with enhanced precision for outpatient and day care treatments. The combination of laser system developments with imaging assisted instruments and advanced endoscopic methods leads to better hemostasis control and sexual function preservation and reduced postoperative issues than traditional surgical methods. The combination of technological advancements with optimized operational procedures and shorter catheterization durations leads to higher physician trust and patient willingness to undergo minimally invasive BPH procedures which supports the expansion of next generation surgical solutions in urology practice.
02
Restraint: High upfront procedure costs and reimbursement uncertainties discourage adoption of advanced benign prostatic hyperplasia surgeries
The high costs of laser prostate surgery platforms and consumables and specialized staff training increase the expense of treating benign prostatic hyperplasia through surgery but hospitals and payers maintain different reimbursement standards which reduce profit margins. The urology devices market experiences revenue growth delays because providers restrict their procedure numbers and delay equipment acquisitions due to restricted coverage of new BPH surgery methods and limited payment for procedures beyond transurethral resection of the prostate.
03
Opportunity: Strategic collaborations between urology device manufacturers and outpatient surgical centers in North America expanding access and Rising demand for minimally invasive Benign Prostatic Hyperplasia Surgical Treatment among aging men in Asia Pacific
North American healthcare providers and insurance companies work together to promote ambulatory prostate surgery procedures because they offer better efficiency. The market shows significant potential for Benign Prostatic Hyperplasia Surgical Treatment because outpatient urology centers and office based labs provide efficient ambulatory models. Device manufacturers team up with integrated delivery networks to provide complete solutions that include capital equipment and disposables and training services which reduce the costs of adoption. The United States will experience its most significant growth through minimally invasive prostate surgery platforms which support conscious sedation procedures in its high volume suburban ambulatory surgery centers and large group urology practices.
The Asia Pacific region experiences three major factors which drive up BPH surgical procedures because its male population ages quickly and health insurance coverage expands and middle class citizens become more health conscious. The current pharmacological treatment of BPH patients who experience ongoing symptoms creates a substantial number of candidates for surgical intervention. Medical facilities now build up their urology departments through the purchase of sophisticated equipment which enables them to perform both laser BPH procedures and office based implant surgeries. The highest procedure growth will occur in China and India and Southeast Asia through day care laser and implant based interventions.
04
Challenge: Growing preference for pharmacologic therapies and office based minimally invasive options is postponing definitive benign prostatic hyperplasia surgery
The implementation of combination drug regimens and minimally invasive BPH procedures in outpatient urology clinics provides symptom relief with reduced perceived risk which leads patients and clinicians to delay or skip Benign Prostatic Hyperplasia Surgical Treatment. The hospital sector experiences reduced growth in BPH surgery procedures performed in both inpatient and day case settings because patients and doctors choose drug treatments and office based procedures over operating room surgeries. The sales duration for advanced surgical systems extends while manufacturers must exercise caution when making capital investments because of decreased demand for operating room procedures.
Supply Chain Landscape
1
Component Sourcing
Boston Scientific CorporationOlympus Corporation
2
BPH Surgery Devices
Boston Scientific CorporationPROCEPT BioRobotics Corporation
3
Minimally Invasive Distribution
Teleflex IncorporatedColoplast Group
4
Clinical Utilization
HospitalsAmbulatory surgical centersUrology clinics
1
Component Sourcing
Boston Scientific CorporationOlympus Corporation
2
BPH Surgery Devices
Boston Scientific CorporationPROCEPT BioRobotics Corporation
3
Minimally Invasive Distribution
Teleflex IncorporatedColoplast Group
4
Clinical Utilization
HospitalsAmbulatory surgical centersUrology clinics
Use Cases of Benign Prostatic Hyperplasia Surgical Treatment in Hospital Settings & Home Care
Hospital Settings : The current hospital revenue from benign prostatic hyperplasia surgical procedures amounts to USD 3.89 billion while the market is projected to expand at 3.4% CAGR from 2025 to 2030 because of increasing demand for BPH surgery in complex cases. The reference procedure for prostate surgery in this environment consists of transurethral resection of the prostate which doctors perform alongside laser prostatectomy techniques including GreenLight vaporization and holmium laser enucleation and Aquablation therapy for treating big or difficult to access prostates. The GreenLight laser and Rezm platforms from Boston Scientific Corporation help hospitals build their portfolios because they allow precise tissue removal which results in shorter hospital stays and better symptom management. The robot assisted Aquablation system from PROCEPT BioRobotics Corporation stands out from other options because it provides uniform tissue removal that does not only depend on prostate size and maintains excellent results for sexual function preservation. The urology departments of many hospitals depend on Olympus Corporation for their visualization and resection infrastructure because they offer advanced endoscopes and energy systems and resectoscopes that optimize prostate surgery through minimally invasive techniques. The hospital based urinary catheter and continence solution products from Coloplast Group help patients recover faster from BPH surgery by minimizing complications and shortening their hospital stay. The UroLift prostatic urethral lift system from Teleflex Incorporated serves as an additional hospital based treatment option for patients who need implant based decompression through UroLift instead of tissue ablation.
Ambulatory Clinics : The ambulatory surgery centers and specialized urology clinics generate USD 1.84 billion in revenue for Benign Prostatic Hyperplasia Surgical Treatment in 2024 and show the fastest growth rate at 6.2% CAGR until 2030 because payers and providers choose same day care. The main surgical procedures performed in this setting include prostate surgery through minimally invasive techniques such as prostatic urethral lift and Rezm water vapor therapy and outpatient GreenLight laser procedures and bipolar transurethral resection of the prostate for specific day case patients. Teleflex Incorporated maintains a dominant market position in ambulatory clinics because its UroLift procedure requires local anesthesia for less than an hour and provides immediate symptom relief and maintains ejaculatory function which appeals to working men who need fast recovery for their normal activities. Boston Scientific Corporation maintains its market position through Rezm and compact laser systems which match ambulatory clinic operations and enable patients to recover without catheters in most situations. The endoscopic platforms from Olympus Corporation enable efficient patient handling through their reliable optics and ergonomic instruments which support office based procedures. The disposable catheters and drainage solutions from Coloplast Group support outpatient and short stay treatment pathways for benign prostatic hyperplasia surgical patients. PROCEPT BioRobotics Corporation expands Aquablation availability to high volume centers which can support robotic BPH surgery investments.
Home Care : The home care sector generates USD 6.74 billion in revenue during 2024 because of its 6.62% annual growth rate until 2030 because of increasing Benign Prostatic Hyperplasia Surgical Treatment episodes that move to early discharge with remote follow up. Home care plays an essential role in post procedural care for patients who undergo UroLift and Rezm and laser prostatectomy and day case transurethral resection of the prostate because it handles catheter care and urinary flow monitoring and treats short term urinary discomfort. The medical care sequence depends on alpha blockers which treat 52.78% of drug requirements and 5 alpha reductase inhibitors which treat 31.26% of cases to control lower urinary tract symptoms and prevent acute urinary retention and achieve better long term results for men with prostate enlargement. The home care segment of Coloplast Group leads the market through its extensive product line of intermittent catheters and drainage bags and discreet continence solutions which minimize infection risks and improve life quality for BPH surgery patients. The market positions of Boston Scientific Corporation and Teleflex Incorporated and PROCEPT BioRobotics Corporation and Olympus Corporation strengthen through their development of implantable devices and endoscopic systems which reduce hospital duration and create safer home recovery paths and structured follow up systems that enhance both patient contentment and Benign Prostatic Hyperplasia Surgical Treatment outcomes.
Recent Developments
The medical field now favors new BPH surgical approaches instead of traditional transurethral resection of the prostate through laser enucleation and UroLift implant and Rezm water vapor therapy procedures. Medical facilities focus on minimizing hospital duration and decreasing bleeding complications and fast recovery of urinary symptoms for patients with lower urinary tract symptoms.
February 2024 : PROCEPT BioRobotics Corporation reported strong global adoption momentum for its Aquablation therapy system for Benign Prostatic Hyperplasia Surgical Treatment, as higher procedure volumes in major urology centers prompted additional AquaBeam Robotic System placements, reinforcing Aquablation therapy as a core minimally invasive BPH procedure and accelerating the shift away from traditional laser BPH surgery in key markets.
November 2023 : Teleflex Incorporated expanded its UroLift prostatic urethral lift technology for Benign Prostatic Hyperplasia Surgical Treatment through new commercial partnerships and hospital contracts in Europe and Asia which enhanced office based minimally invasive BPH procedure availability and boosted Teleflexs market position against other BPH device competitors.
June 2023 : The company expanded physician training programs for Rezm water vapor therapy and GreenLight laser platforms which treat benign prostatic hyperplasia through minimally invasive procedures, leading to increased BPH procedure adoption and shorter hospital stays compared to TURP and strengthening Boston Scientifics position in BPH surgical practice evolution.
Impact of Industry Transitions on the Benign Prostatic Hyperplasia Surgical Treatment Market
As a core segment of the Pharmaceutical industry,
the Benign Prostatic Hyperplasia Surgical Treatment market develops in line with broader industry shifts.
Over recent years, transitions such as Shift to Minimally Invasive Care and Digital and Data Driven Pathways have redefined priorities
across the Pharmaceutical sector,
influencing how the Benign Prostatic Hyperplasia Surgical Treatment market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Shift to Minimally Invasive Care
The shift towards minimally invasive surgical techniques for benign prostatic hyperplasia is transforming the urology landscape, particularly in the U.S. and China. This transition is driving hospitals to reduce inpatient bed usage while reallocating investments towards advanced endoscopic systems and laser treatment equipment. As outpatient facilities increasingly adopt vaporization and enucleation methods over traditional transurethral resection, there is a strategic imperative for anesthesia services and surgical centers to adapt in order to secure favorable reimbursement terms from insurers. This evolution is projected to generate an additional $484 million in revenue for the BPH surgical treatment market by 2030, underscoring the significant economic impact of this paradigm shift in patient care.
02
Digital and Data Driven Pathways
The development of surgical treatments for benign prostatic hyperplasia now incorporates image guided decision pathways which use data analytics and hospital information systems and telehealth monitoring for post operative care. The combination of advanced diagnostic methods and predictive analytical tools helps doctors choose between surgical BPH treatment and pharmacotherapy and active surveillance which transforms how patients get referred between primary care and radiology services. The development of robotics ready platforms and navigation tools leads to investments between BPH surgery and colorectal and gynecologic procedures which creates standardized training programs and service line financial models. The transition to value based care models becomes faster because it enables organizations to implement bundled payment systems and track real world results and establish collaborative perioperative care coordination between different medical specialties.